Tekla Capital Management
Tekla Capital Management is an investment adviser.
Business Model:
Revenue: $25.7M
Employees: 51-200
Rankings
Industries / Tags:
Detailed Tekla Capital Management Information
Geographic Data
Address: 100 Federal St
City: Boston
State: MA
Zip: 02110
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Linkedin
Crunchbase
Metrics
2,103,477Website Global Rank
9,482Website Monthly Traffic
Twitter Followers
Description
Tekla Capital Management LLC is a registered investment adviser based in Boston, Massachusetts, and is currently the investment adviser for two closed-end equity funds, H&a;Q Healthcare Investors and H&a;Q Life Sciences Investors. The Funds invest in growth equities, both public and private, in the healthcare and life sciences industries.
Contact Phone:
+16177728500
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 4/2020 | Dynacure | Series C | 54.2M |
| 3/2023 | Oculis | Post-IPO Equity | 0 |
| 5/2021 | Oculis | Series C | 0 |
| 7/2018 | Sutro Biopharma | Series E | 0 |
| 3/2015 | Veniti | Series C | 0 |
| 5/2018 | Rainier Therapeutics | Series B | 20M |
| 3/2021 | Pyxis Oncology | Series B | 152M |
| 6/2021 | ImmuneID | Series A | 0 |
| 9/2018 | Atreca | Series C | 125M |
| 5/2020 | HotSpot Therapeutics | Series B | 65M |
| 4/2014 | Neurovance | Series A | 6.3M |
| 10/2018 | CuraSen Therapeutics | Series A | 54.5M |
| 8/2018 | Therachon | Series B | 60M |
| 9/2018 | Galera Therapeutics | Series C | 70M |
| 1/2020 | VectivBio | Series A | 35M |
| 10/2013 | Insightra Medical | Series C | - |
| 5/2022 | Invetx | Series B | 0 |
| 1/2019 | Oculis | Series B | 15.7M |
| 11/2019 | Arkuda Therapeutics | Series A | 44M |
| 9/2019 | Amphivena Therapeutics | Series C | 0 |
| 1/2001 | CytoLogix | Series B | 0 |
| 10/2020 | Priothera | Series A | 0 |
| 9/2012 | IlluminOss Medical | Series C | 0 |
| 11/2006 | Magellan Diagnostics | Private Equity Round | 0 |
| 3/2013 | CardioKinetix | Series E | 23M |
| 5/2021 | BioTheryX | Series E | 92M |
| 2/2022 | Endeavor BioMedicines | Series B | 101M |
| 4/2015 | Merus | Series C | 79.1M |
| 3/2021 | Caribou Biosciences | Series C | 115M |
| 10/2021 | ReCode Therapeutics | Series B | 0 |
| 3/2017 | Rainier Therapeutics | Series B | 30M |
| 11/2021 | Quell Therapeutics | Series B | 0 |
| 10/2018 | Milestone Pharmaceuticals | Series D | 80M |
| 8/2015 | Ovid Therapeutics | Series B | 75M |
| 6/2015 | CytomX Therapeutics | Series D | 70M |
| 2/2022 | Arkuda Therapeutics | Series B | 0 |
| 1/2016 | Rainier Therapeutics | Series A | 13M |
| 10/2020 | VectivBio | Equity | 110M |
| 9/2020 | Invetx | Series A | 0 |
| 11/2021 | Arbor Biotechnologies | Series B | 0 |
| 7/2007 | Agensys | Series D | 41.3M |
| 1/2023 | Amolyt Pharma | Series C | 0 |
| 10/2011 | Puma Biotechnology | Post-IPO Equity | 55M |
| 11/2021 | Parthenon Therapeutics | Series A | 0 |
| 7/2021 | Aristea Therapeutics | Series B | 0 |
| 7/2015 | Afferent Pharmaceuticals | Series C | 55M |
| 4/2022 | MoonLake Immunotherapeutics | Post-IPO Equity | 115M |
| 4/2020 | Rallybio | Series B | 0 |
| 8/2017 | Milestone Pharmaceuticals | Series C | 55M |
| 5/2022 | Invetx | Series B | 0 |
| 4/2022 | MoonLake Immunotherapeutics | Post-IPO Equity | 0 |
| 2/2022 | Arkuda Therapeutics | Series B | 0 |
| 2/2022 | Endeavor BioMedicines | Series B | 0 |
| 11/2021 | Quell Therapeutics | Series B | 0 |
| 11/2021 | Arbor Biotechnologies | Series B | 0 |
| 11/2021 | Parthenon Therapeutics | Series A | 0 |
| 10/2021 | ReCode Therapeutics | Series B | 0 |
| 7/2021 | Aristea Therapeutics | Series B | 0 |
| 6/2021 | ImmuneID | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
